The institutional investor owned 178,731 shares of the biopharmaceutical company’s stock after selling 14,842 shares during the quarter. Geneos Wealth Management Inc. now owns 756 shares of the biopharmaceutical company’s stock worth $46,000 after acquiring an additional 588 shares during the period. Following the sale, the executive vice president directly owned 35,929 shares of the company’s stock, valued at approximately $2,509,999.94. Following the completion of the sale, the executive vice president owned 37,630 shares of the company’s stock, valued at $2,628,831.80. Over the last three months, insiders have sold 55,777 shares of company stock valued at $3,818,215.